Data analysis confirms BPH as progressive disease

Results from a recent study that systematically analyzed the data of placebo-controlled trials in patients with BPH confirm that BPH is a progressive disease on the basis of worsening prostate volume, maximum urinary flow, and symptom score, as well as the rate of prostate-related surgery and acute urinary retention.

Related Videos

Related Content

Advertisement

December 3rd 2024

JANX007 demonstrates encouraging clinical activity in mCRPC

Hannah Clarke

Data showed that all patients achieved a PSA decline of at least 50%.

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 2nd 2024

Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer

Hannah Clarke

“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says Arnold I. Chin, MD, PhD.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

November 27th 2024

Phase 2 trial launches of autologous prostate cancer vaccine

Hannah Clarke

The phase 2 CELLVX-230 trial is exploring the potential of FK-PC101 to delay or prevent prostate cancer recurrence following prostatectomy.

November 27th 2024

Final rule: Conversion factor set for 2.83% reduction in 2025

Jonathan Rubenstein, MD Mark Painter

"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and Mark Painter.

Related Content

Advertisement

December 3rd 2024

JANX007 demonstrates encouraging clinical activity in mCRPC

Hannah Clarke

Data showed that all patients achieved a PSA decline of at least 50%.

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 2nd 2024

Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer

Hannah Clarke

“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says Arnold I. Chin, MD, PhD.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

November 27th 2024

Phase 2 trial launches of autologous prostate cancer vaccine

Hannah Clarke

The phase 2 CELLVX-230 trial is exploring the potential of FK-PC101 to delay or prevent prostate cancer recurrence following prostatectomy.

November 27th 2024

Final rule: Conversion factor set for 2.83% reduction in 2025

Jonathan Rubenstein, MD Mark Painter

"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and Mark Painter.